{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:48:28Z","timestamp":1794584908090,"version":"4.9.1"},"reference-count":237,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacc.2026.05.037","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:12:04Z","timestamp":1782850324000},"page":"1284-1313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement"],"prefix":"10.1016","volume":"88","author":[{"given":"Dharam J.","family":"Kumbhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kinlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy W.","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline E.","family":"Tamis-Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W.A.","family":"Verheugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.05.037_bib1","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib2","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2024.06.013","article-title":"2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"84","author":"Thompson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib3","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib4","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib5","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jacc.2025.12.027","article-title":"Cardiovascular statistics in the United States, 2026: JACC Stats","volume":"87","author":"Wadhera","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib6","first-page":"e41","article-title":"2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/01.RES.0000252802.25497.b7","article-title":"Platelets as immune cells: bridging inflammation and cardiovascular disease","volume":"100","author":"von Hundelshausen","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2026.05.037_bib8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/01.RES.0000264509.36234.51","article-title":"Clinical aspects of platelet inhibitors and thrombus formation","volume":"100","author":"Meadows","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2026.05.037_bib9","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","article-title":"Acetylation of prostaglandin synthase by aspirin","volume":"72","author":"Roth","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2026.05.037_bib10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0955-0674(94)90096-5","article-title":"Adhesive signaling in platelets","volume":"6","author":"Shattil","year":"1994","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jacc.2026.05.037_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2026.05.037_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12170-014-0430-5","article-title":"State-of-the-art: hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus","volume":"9","author":"Kumbhani","year":"2015","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.jacc.2026.05.037_bib13","doi-asserted-by":"crossref","DOI":"10.31083\/RCM36522","article-title":"Antiplatelet therapy in heart disease","volume":"26","author":"Ozyuncu","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.amjmed.2006.01.023","article-title":"Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials","volume":"119","author":"Bavry","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib15","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib16","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib17","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib18","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","article-title":"Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials","volume":"125","author":"Bangalore","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib19","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib21","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib22","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes: developed by the Task Force for the Management of Chronic Coronary Syndromes of the European Society of Cardiology (ESC)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib23","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2025.01.018","article-title":"2025 acute coronary syndromes guideline-at-a-glance","volume":"85","author":"Kumbhani","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMra1607714","article-title":"Management of antithrombotic therapy after acute coronary syndromes","volume":"384","author":"Rodriguez","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib25","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jacc.2023.07.031","article-title":"Comparison of antiplatelet monotherapies after percutaneous coronary intervention according to clinical, ischemic, and bleeding risks","volume":"82","author":"Yang","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2023.05.022","article-title":"The optimal antiplatelet agent for secondary prevention of coronary artery disease: ring out the old?","volume":"82","author":"Kumbhani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib28","article-title":"2026 guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"2026","author":"Prabhakaran","year":"2026","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.05.037_bib29","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamacardio.2020.6814","article-title":"Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC-high bleeding risk trade-off model","volume":"6","author":"Urban","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib31","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005795","article-title":"Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease: a patient-level meta-analysis","volume":"11","author":"Elmariah","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.05.037_bib33","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1161\/STROKEAHA.120.031755","article-title":"Balancing benefits and risks of long-term antiplatelet therapy in noncardioembolic transient ischemic attack or stroke","volume":"52","author":"Hilkens","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.05.037_bib34","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib35","article-title":"Clinical usefulness of PRECISE-DAPT score for predicting bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an analysis from the SMART-DATE randomized trial","volume":"13","author":"Choi","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.05.037_bib36","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2014.2630","article-title":"Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations","volume":"311","author":"Muntner","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"40","author":"Mahmoud","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib40","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/eurheartj\/ehy872","article-title":"The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin","volume":"40","author":"Valgimigli","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/archinte.164.1.40","article-title":"Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses","volume":"164","author":"Hennekens","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib43","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.119.045010","article-title":"Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019: the MESA study (Multi-Ethnic Study of Atherosclerosis)","volume":"141","author":"Cainzos-Achirica","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacc.2026.05.037_bib44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamacardio.2020.4939","article-title":"Value of coronary artery calcium scanning in association with the net benefit of aspirin in primary prevention of atherosclerotic cardiovascular disease","volume":"6","author":"Ajufo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2026.05.037_bib46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2026.05.037_bib47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib48","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib50","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib51","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib52","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib53","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2025.5057","article-title":"Ticagrelor vs prasugrel in patients with diabetes and multivessel coronary artery disease: the TUXEDO-2 randomized clinical trial","author":"Bangalore","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib54","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCOUTCOMES.113.000120","article-title":"Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction","volume":"6","author":"Roe","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.05.037_bib56","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib57","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa2508808","article-title":"Early discontinuation of aspirin after PCI in low-risk acute myocardial infarction","volume":"393","author":"Tarantini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib58","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib59","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1305978","article-title":"Platelet inhibition with cangrelor during PCI","volume":"369","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib60","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib61","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib62","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/S0140-6736(13)61840-1","article-title":"Cangrelor: a new CHAMPION for percutaneous coronary intervention","volume":"382","author":"Mehta","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib63","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib64","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib65","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2023.10.013","article-title":"Clopidogrel vs aspirin monotherapy beyond 1 year after percutaneous coronary intervention","volume":"83","author":"Watanabe","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib67","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa2507980","article-title":"Early withdrawal of aspirin after PCI in acute coronary syndromes","volume":"393","author":"Guimar\u00e3es","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib68","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib69","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.05.037_bib70","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2026.05.037_bib71","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamacardio.2024.3216","article-title":"Short-term dual antiplatelet therapy after drug-eluting stenting in patients with acute coronary syndromes: a systematic review and network meta-analysis","volume":"9","author":"Carvalho","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib72","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib73","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib74","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (Timing Of Platelet Inhibition After Acute Coronary Syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib75","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib76","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib77","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes","volume":"15","author":"Laudani","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.05.037_bib78","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib79","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib80","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib81","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib82","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib83","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.123.064264","article-title":"Comparison of 3- to 6-month versus 12-month dual antiplatelet therapy after coronary intervention using the contemporary drug-eluting stents with ultrathin struts: the HOST-IDEA randomized clinical trial","volume":"147","author":"Han","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib84","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib85","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib86","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib87","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2508026","article-title":"Ticagrelor and aspirin or aspirin alone after coronary surgery for acute coronary syndrome","volume":"393","author":"Jeppsson","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib88","article-title":"Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis","volume":"367","author":"Solo","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.05.037_bib89","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijcard.2018.07.083","article-title":"Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: an updated meta-analysis","volume":"269","author":"Cardoso","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib90","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","article-title":"A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction","volume":"1","author":"Elwood","year":"1974","journal-title":"Br Med J"},{"key":"10.1016\/j.jacc.2026.05.037_bib91","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(79)92808-3","article-title":"Aspirin and secondary mortality after myocardial infarction","volume":"2","author":"Elwood","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib92","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/01.CIR.62.3.449","article-title":"Persantine and aspirin in coronary heart disease","volume":"62","year":"1980","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib93","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM198010303031804","article-title":"Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project","volume":"303","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib94","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.1980.03300330019023","article-title":"A randomized, controlled trial of aspirin in persons recovered from myocardial infarction","volume":"243","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib95","first-page":"V63","article-title":"The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction","volume":"62","author":"Breddin","year":"1980","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.05.037_bib97","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Antithrombotic Trialists\u2019 (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib98","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib99","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib100","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib101","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib102","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib103","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","article-title":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial","volume":"405","author":"Choi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib104","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(26)00422-8","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial","volume":"407","author":"Kang","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib105","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1093\/eurheartj\/ehz185","article-title":"Randomized trial of ticagrelor vs aspirin in patients after coronary artery bypass grafting: the TiCAB trial","volume":"40","author":"Schunkert","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib106","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2018.3197","article-title":"Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial","volume":"319","author":"Zhao","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJM199007193230302","article-title":"The effect of warfarin on mortality and reinfarction after myocardial infarction","volume":"323","author":"Smith","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib108","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib109","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2015.06.027","article-title":"Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 trial","volume":"66","author":"Hess","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib112","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib113","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"suppl B","key":"10.1016\/j.jacc.2026.05.037_bib114","doi-asserted-by":"crossref","first-page":"B42","DOI":"10.1016\/S0149-2918(98)80029-5","article-title":"Clinical safety and efficacy of clopidogrel\u2014implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease","volume":"20","author":"Ferguson","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacc.2026.05.037_bib115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib116","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib117","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(25)00562-8","article-title":"Clopidogrel use in chronic coronary syndrome: a fragile lifelong choice","volume":"405","author":"Rossello","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib118","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial","volume":"71","author":"Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib119","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib121","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib122","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10072-024-07821-0","article-title":"Early antiplatelet therapy after intravenous thrombolysis for acute ischemic stroke: a systematic review and meta-analysis","volume":"46","author":"Kelani","year":"2025","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jacc.2026.05.037_bib123","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(12)60949-0","article-title":"Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial","volume":"380","author":"Zinkstok","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib124","doi-asserted-by":"crossref","first-page":"86","DOI":"10.36011\/cpp.2021.3.e10","article-title":"Antiplatelet therapy for secondary stroke prevention in patients with ischemic stroke or transient ischemic attack","volume":"3","author":"Lee","year":"2021","journal-title":"Cardiovasc Prev Pharmacother"},{"key":"10.1016\/j.jacc.2026.05.037_bib125","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/STR.0000000000000377","article-title":"Benefits and risks of dual versus single antiplatelet therapy for secondary stroke prevention: a systematic review for the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack","volume":"52","author":"Brown","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.05.037_bib126","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib127","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib128","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2309137","article-title":"Dual antiplatelet treatment up to 72 hours after ischemic stroke","volume":"389","author":"Gao","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib130","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jacc.2026.05.037_bib131","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jacc.2026.05.033","article-title":"Direct oral anticoagulants in primary and secondary prevention of thrombotic events: 2026 ACC scientific statement: a report of the American College of Cardiology","volume":"88","author":"Kumbhani","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib132","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(24)02197-4","article-title":"Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial","volume":"404","author":"Werring","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib133","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1474-4422(15)70018-9","article-title":"Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial","volume":"14","author":"Markus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2026.05.037_bib134","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.05.037_bib135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/jcdd11020048","article-title":"Dual antiplatelet therapy for the acute management and long-term secondary prevention of ischemic stroke and transient ischemic attack, an updated review","volume":"11","author":"Chan","year":"2024","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.jacc.2026.05.037_bib136","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"Benavente","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib137","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jamaneurol.2023.3931","article-title":"Atrial fibrillation in patients with stroke attributed to large- or small-vessel disease: 3-year results from the STROKE AF randomized clinical trial","volume":"80","author":"Bernstein","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2026.05.037_bib138","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib139","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib140","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib141","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib142","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa2507532","article-title":"Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation","volume":"393","author":"Lemesle","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib143","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2024.12.030","article-title":"Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease: meta-analysis of randomized trials","volume":"85","author":"Rashedi","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib144","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib145","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib146","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib147","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib148","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.jacc.2017.02.012","article-title":"Use of antiplatelet therapy\/DAPT for post-PCI patients undergoing noncardiac surgery","volume":"69","author":"Banerjee","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib149","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib150","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib151","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/1060028018824640","article-title":"Perioperative bridging with glycoprotein IIb\/IIIa inhibitors versus cangrelor: balancing efficacy and safety","volume":"53","author":"Van Tuyl","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacc.2026.05.037_bib152","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100047","article-title":"Bentracimab for ticagrelor reversal in patients undergoing urgent surgery","volume":"1","author":"Bhatt","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jacc.2026.05.037_bib153","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3390\/jcm9072318","article-title":"Management of bleeding events associated with antiplatelet therapy: evidence, uncertainties and pitfalls","volume":"9","author":"Godier","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib154","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.jcin.2024.08.027","article-title":"International consensus statement on platelet function and genetic testing in percutaneous coronary intervention: 2024 update","volume":"17","author":"Angiolillo","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.05.037_bib155","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib156","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","article-title":"Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation","volume":"29","author":"Price","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib157","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib158","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib159","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.jacc.2007.11.080","article-title":"The role of aspirin in cardiovascular prevention: implications of aspirin resistance","volume":"51","author":"Gasparyan","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib160","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib161","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.jacc.2007.07.051","article-title":"Platelet function monitoring in patients with coronary artery disease","volume":"50","author":"Gurbel","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib162","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1161\/01.CIR.0000147228.29325.F9","article-title":"Platelet function testing in cardiovascular diseases","volume":"110","author":"Michelson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib163","first-page":"597","article-title":"What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?","volume":"66","author":"Tantry","year":"2005","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.05.037_bib164","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib165","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib166","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","article-title":"Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events","volume":"160","author":"Gurbel","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib167","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrcardio.2010.71","article-title":"Overcoming \u201cresistance\u201d to antiplatelet therapy: targeting the issue of nonadherence","volume":"7","author":"Kolandaivelu","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib168","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.amjmed.2013.01.033","article-title":"Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis","volume":"126","author":"Kumbhani","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib169","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib170","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib171","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Par\u00e9","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib172","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-pharmtox-051921-092701","article-title":"Pharmacogenetics of antiplatelet therapy","volume":"63","author":"Castrichini","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jacc.2026.05.037_bib173","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jcin.2012.07.015","article-title":"CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome","volume":"5","author":"Cuisset","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.05.037_bib174","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/0091270009355161","article-title":"Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans","volume":"50","author":"Man","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.05.037_bib175","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","article-title":"The CYP2C19 enzyme polymorphism","volume":"61","author":"Wedlund","year":"2000","journal-title":"Pharmacology"},{"key":"10.1016\/j.jacc.2026.05.037_bib176","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.05.037_bib177","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib178","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib179","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib180","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib181","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.ATV.3.4.383","article-title":"Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin","volume":"3","author":"Rao","year":"1983","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jacc.2026.05.037_bib182","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1476-5381.2009.00243.x","article-title":"The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers","volume":"157","author":"Schuijt","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacc.2026.05.037_bib183","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib184","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib185","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib186","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","article-title":"Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently","volume":"81","author":"Farid","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.05.037_bib187","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","author":"Siller-Matula","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib188","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/hrt.2009.171488","article-title":"Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition","volume":"96","author":"Gremmel","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2026.05.037_bib189","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/eurheartj\/ehq023","article-title":"Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel","volume":"31","author":"Sibbing","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib190","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/17512433.2022.2121702","article-title":"Clinical pharmacology of antiplatelet drugs","volume":"15","author":"Gelbenegger","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.05.037_bib191","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","article-title":"Clopidogrel-drug interactions","volume":"57","author":"Bates","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib192","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/j.1538-7836.2010.03925.x","article-title":"Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel","volume":"8","author":"Judge","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.037_bib193","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jacc.2022.08.800","article-title":"Cardiovascular drug interactions with nirmatrelvir\/ritonavir in patients with COVID-19: JACC Review Topic of the Week","volume":"80","author":"Abraham","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib194","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib195","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2009.05.050","article-title":"Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study","volume":"54","author":"Cuisset","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib196","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib197","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O\u2019Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib198","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the Platelet Inhibition and Patient Outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib199","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib200","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCOUTCOMES.114.001223","volume":"8","author":"Mathews","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.05.037_bib201","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1503\/cmaj.081913","article-title":"Long-term trends in use of and expenditures for cardiovascular medications in Canada","volume":"181","author":"Jackevicius","year":"2009","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.jacc.2026.05.037_bib202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCOUTCOMES.109.902031","article-title":"Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care","volume":"3","author":"Ho","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.05.037_bib203","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.037_bib204","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1185\/03007995.2010.551657","article-title":"Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention","volume":"27","author":"Zhu","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2026.05.037_bib205","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.4244\/EIJV7I12A221","article-title":"Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database","volume":"7","author":"Latry","year":"2012","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2026.05.037_bib206","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018481","article-title":"Premature discontinuation of dual antiplatelet therapy after coronary stenting in veterans: characteristics and long-term outcomes","volume":"10","author":"Kinlay","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.05.037_bib207","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib208","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/CIRCULATIONAHA.106.618066","article-title":"Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry","volume":"113","author":"Spertus","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.037_bib209","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib210","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4244\/EIJV8I9A159","article-title":"Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial","volume":"8","author":"Dangas","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2026.05.037_bib211","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jcin.2014.10.017","article-title":"Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy","volume":"8","author":"Cutlip","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.05.037_bib212","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/11598500-000000000-00000","article-title":"Under-prescribing and non-adherence to medications after coronary bypass surgery in older adults: strategies to improve adherence","volume":"29","author":"Sengstock","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jacc.2026.05.037_bib213","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.acvd.2010.05.003","article-title":"Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization","volume":"103","author":"Tuppin","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2026.05.037_bib214","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.jacc.2019.03.470","article-title":"Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC Review Topic of the Week","volume":"73","author":"Arora","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib215","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijcard.2009.04.033","article-title":"Impact of the community\u2019s socioeconomic status on characteristics and outcomes of patients undergoing percutaneous coronary intervention","volume":"144","author":"Shimony","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib216","first-page":"123","article-title":"[Socioeconomic position and appropriate antiplatelet therapy after percutaneous coronary intervention: a population-based cohort study in Rome (Lazio Region, Central Italy)]","volume":"38","author":"Mayer","year":"2014","journal-title":"Epidemiol Prev"},{"key":"10.1016\/j.jacc.2026.05.037_bib217","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/03007995.2016.1182901","article-title":"Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials","volume":"32","author":"Kubica","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2026.05.037_bib218","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1185\/03007991003670563","article-title":"Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors","volume":"26","author":"Burke","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2026.05.037_bib219","first-page":"290","article-title":"Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome","volume":"16","author":"Philipson","year":"2010","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jacc.2026.05.037_bib220","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jacc.2014.11.034","article-title":"Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study","volume":"65","author":"Cowper","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib221","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamacardio.2018.1813","article-title":"Association of out-of-pocket annual health expenditures with financial hardship in low-income adults with atherosclerotic cardiovascular disease in the united states","volume":"3","author":"Khera","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib222","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jama.2018.19791","article-title":"Effect of medication co-payment vouchers on P2Y12 inhibitor use and major adverse cardiovascular events among patients with myocardial infarction: the ARTEMIS randomized clinical trial","volume":"321","author":"Wang","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib223","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/JCN.0b013e3181ae7b2a","article-title":"Exploring patients\u2019 reasons for discontinuance of heart medications","volume":"24","author":"Garavalia","year":"2009","journal-title":"J Cardiovasc Nurs"},{"key":"10.1016\/j.jacc.2026.05.037_bib224","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1345\/aph.1L236","article-title":"Barriers to clopidogrel adherence following placement of drug-eluting stents","volume":"43","author":"Pallares","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacc.2026.05.037_bib225","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.037_bib226","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib227","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.amjcard.2011.07.038","article-title":"Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes","volume":"108","author":"Armero","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib228","first-page":"555","article-title":"Dyspnoea management in acute coronary syndrome patients treated with ticagrelor","volume":"4","author":"Parodi","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jacc.2026.05.037_bib229","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamacardio.2016.0001","article-title":"Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction","volume":"1","author":"Faridi","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib230","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.037_bib231","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.amjcard.2014.08.010","article-title":"Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST\u2013segment elevation myocardial infarction","volume":"114","author":"Rymer","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib232","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1592\/phco.27.8.1145","article-title":"Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative","volume":"27","author":"Bottorff","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2026.05.037_bib233","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1001\/jama.288.22.2868","article-title":"Interventions to enhance patient adherence to medication prescriptions: scientific review","volume":"288","author":"McDonald","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.037_bib234","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.clinthera.2013.05.015","volume":"35","author":"Jung","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacc.2026.05.037_bib235","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/09537104.2016.1206197","article-title":"Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: the ACCEL-COMBO trial","volume":"28","author":"Koh","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2026.05.037_bib236","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41569-023-00854-6","article-title":"Current concepts and novel targets for antiplatelet therapy","volume":"20","author":"Gawaz","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.05.037_bib238","article-title":"Zalunfiban at first medical contact for ST-elevation myocardial infarction","volume":"5","author":"Van\u2019t Hof","year":"2026","journal-title":"NEJM Evid"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726067045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726067045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:47:12Z","timestamp":1789483632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726067045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":237,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0735109726067045"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.037","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}